← Back to All US Stocks

CDRE Stock Analysis - Cadre Holdings, Inc. AI Rating

CDRE NYSE Orthopedic, Prosthetic & Surgical Appliances & Supplies DE CIK: 0001860543
Recently Updated • Analysis: Mar 22, 2026 • SEC Data: 2025-12-31
AI Rating
BUY
78% Confidence

📊 CDRE Key Takeaways

Revenue: $610.3M
Net Margin: 7.2%
Free Cash Flow: $56.8M
Current Ratio: 3.50x
Debt/Equity: 0.92x
EPS: $1.02
AI Rating: BUY with 78% confidence

Investment Thesis

Cadre Holdings demonstrates solid operational fundamentals with healthy revenue growth of 7.5% YoY and strong free cash flow generation of $56.8M (9.3% FCF margin). The company maintains excellent financial health with a 3.5x current ratio, robust interest coverage of 41.1x, and moderate leverage at 0.92x debt-to-equity, providing flexibility for strategic investments or debt reduction.

CDRE Strengths

  • + Strong liquidity position with $122.9M cash and 3.5x current ratio enabling operational flexibility
  • + Excellent interest coverage ratio of 41.1x indicating minimal financial distress risk
  • + Robust free cash flow generation of $56.8M with 9.3% FCF margin supporting shareholder returns or growth investments
  • + Healthy gross margin of 42.5% demonstrating pricing power and operational efficiency in surgical appliances sector
  • + Moderate leverage of 0.92x debt-to-equity providing balance sheet stability

CDRE Risks

  • ! Revenue growth of 7.5% is modest for a specialized medical devices company, suggesting market maturity or competitive pressures
  • ! Net income flat YoY despite revenue growth indicates margin compression or increased operating expenses requiring investigation
  • ! Long-term debt of $291M represents 37.8% of total assets, limiting financial flexibility despite manageable coverage ratios
  • ! Operating margin of 11.0% is relatively thin for orthopedic/surgical appliances sector, leaving limited buffer for cost increases

Key Metrics to Watch

CDRE Financial Metrics

Revenue
$610.3M
Net Income
$44.1M
EPS (Diluted)
$1.02
Free Cash Flow
$56.8M
Total Assets
$770.0M
Cash Position
$122.9M

💡 AI Analyst Insight

Strong liquidity with a 3.50x current ratio provides a solid financial cushion.

CDRE Profitability Ratios

Gross Margin 42.5%
Operating Margin 11.0%
Net Margin 7.2%
ROE 13.9%
ROA 5.7%
FCF Margin 9.3%

CDRE vs Default Sector

How Cadre Holdings, Inc. compares to Default sector averages

Net Margin
CDRE 7.2%
vs
Sector Avg 12.0%
CDRE Sector
ROE
CDRE 13.9%
vs
Sector Avg 15.0%
CDRE Sector
Current Ratio
CDRE 3.5x
vs
Sector Avg 1.8x
CDRE Sector
Debt/Equity
CDRE 0.9x
vs
Sector Avg 0.7x
CDRE Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

CDRE Balance Sheet & Liquidity

Current Ratio
3.50x
Quick Ratio
2.54x
Debt/Equity
0.92x
Debt/Assets
58.7%
Interest Coverage
41.14x
Long-term Debt
$291.0M

CDRE 5-Year Financial Trend

CDRE 5-year financial data: Year 2021: Revenue $427.3M, Net Income $38.5M, EPS $1.40. Year 2022: Revenue $457.8M, Net Income $12.7M, EPS $0.44. Year 2023: Revenue $482.5M, Net Income $12.7M, EPS $0.44. Year 2024: Revenue $567.6M, Net Income $5.8M, EPS $0.16. Year 2025: Revenue $610.3M, Net Income $38.6M, EPS $1.02.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Cadre Holdings, Inc.'s revenue has grown significantly by 43% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.02 reflects profitable operations.

CDRE Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
9.3%
Free cash flow / Revenue

CDRE Quarterly Performance

Quarterly financial performance data for Cadre Holdings, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $109.4M $3.7M $0.09
Q2 2025 $144.3M $6.9M $0.30
Q1 2025 $130.1M $6.9M $0.18
Q3 2024 $109.4M $3.7M $0.09
Q2 2024 $121.1M $6.9M $0.29
Q1 2024 $111.7M $6.9M $0.18
Q3 2023 $111.6M -$779.0K $-0.02
Q2 2023 $118.2M $4.4M $0.12

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

CDRE Capital Allocation

Operating Cash Flow
$63.7M
Cash generated from operations
Capital Expenditures
$6.9M
Investment in assets
Dividends Paid
$15.4M
Returned to shareholders

CDRE SEC Filings

Access official SEC EDGAR filings for Cadre Holdings, Inc. (CIK: 0001860543)

📋 Recent SEC Filings

Date Form Document Action
Mar 20, 2026 4 xslF345X06/tm269192-3_4seq1.xml View →
Mar 20, 2026 4 xslF345X06/tm269192-2_4seq1.xml View →
Mar 20, 2026 4 xslF345X06/tm269192-1_4seq1.xml View →
Mar 17, 2026 4 xslF345X05/tm268980-3_4seq1.xml View →
Mar 17, 2026 4 xslF345X05/tm268980-1_4seq1.xml View →

Frequently Asked Questions about CDRE

What is the AI rating for CDRE?

Cadre Holdings, Inc. (CDRE) has an AI rating of BUY with 78% confidence, based on fundamental analysis of SEC EDGAR filings.

What are CDRE's key strengths?

Strong liquidity position with $122.9M cash and 3.5x current ratio enabling operational flexibility. Excellent interest coverage ratio of 41.1x indicating minimal financial distress risk.

What are the risks of investing in CDRE?

Revenue growth of 7.5% is modest for a specialized medical devices company, suggesting market maturity or competitive pressures. Net income flat YoY despite revenue growth indicates margin compression or increased operating expenses requiring investigation.

What is CDRE's revenue and growth?

Cadre Holdings, Inc. reported revenue of $610.3M.

Does CDRE pay dividends?

Cadre Holdings, Inc. pays dividends, with $15.4M distributed to shareholders in the trailing twelve months.

Where can I find CDRE SEC filings?

Official SEC filings for Cadre Holdings, Inc. (CIK: 0001860543) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CDRE's EPS?

Cadre Holdings, Inc. has a diluted EPS of $1.02.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 22, 2026 | Data as of: 2025-12-31 | Powered by Claude AI